Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome

[1]  D. Mallardo,et al.  Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma , 2020, Clinical Cancer Research.

[2]  E. Choi,et al.  CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy , 2020, Cancer Immunology Research.

[3]  G. Gao,et al.  Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5 , 2018, Proceedings of the National Academy of Sciences.

[4]  S. M. Toor,et al.  Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.

[5]  Thomas D. Wu,et al.  CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1 , 2018, Proceedings of the National Academy of Sciences.

[6]  T. Owonikoko,et al.  Immune checkpoint inhibitors in small cell lung cancer. , 2018, Journal of thoracic disease.

[7]  S. Jonjić,et al.  Targeting PVR (CD155) and its receptors in anti-tumor therapy , 2018, Cellular & Molecular Immunology.

[8]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[9]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[10]  Wei Wang,et al.  CD155, an onco‐immunologic molecule in human tumors , 2017, Cancer science.

[11]  J. Li,et al.  Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages , 2017, Scientific Reports.

[12]  Young Hak Kim,et al.  Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients , 2017, Scientific Reports.

[13]  J. Park,et al.  Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer. , 2017, Gene.

[14]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[15]  J. Park,et al.  PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy , 2016, Scientific Reports.

[16]  S. Candéias,et al.  The Immune System in Cancer Prevention, Development and Therapy. , 2015, Anti-cancer agents in medicinal chemistry.

[17]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  Z. Qiu,et al.  CD226 gene polymorphisms are associated with non-small-cell lung cancer in the Chinese Han population , 2015, Therapeutics and clinical risk management.

[19]  K. Shimada,et al.  Clinical significance of CD155 expression in human pancreatic cancer. , 2015, Anticancer research.

[20]  G. Beatty,et al.  Immune Escape Mechanisms as a Guide for Cancer Immunotherapy , 2014, Clinical Cancer Research.

[21]  L. Galluzzi,et al.  Novel immune checkpoint blocker approved for the treatment of advanced melanoma , 2014, Oncoimmunology.

[22]  S. R. Matioli,et al.  CD226 rs763361 Is Associated with the Susceptibility to Type 1 Diabetes and Greater Frequency of GAD65 Autoantibody in a Brazilian Cohort , 2014, Mediators of inflammation.

[23]  F. Hodi,et al.  CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients , 2013, Clinical Cancer Research.

[24]  D. Hafler,et al.  The CD226/CD155 Interaction Regulates the Proinflammatory (Th1/Th17)/Anti-Inflammatory (Th2) Balance in Humans , 2013, The Journal of Immunology.

[25]  M. Kalos,et al.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.

[26]  Z. Qiu,et al.  CD226 Gly307Ser association with multiple autoimmune diseases: a meta-analysis. , 2013, Human immunology.

[27]  Eurie L. Hong,et al.  Annotation of functional variation in personal genomes using RegulomeDB , 2012, Genome research.

[28]  J. McCubrey,et al.  Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma , 2012, Oncotarget.

[29]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[30]  L. Zitvogel,et al.  The secret ally: immunostimulation by anticancer drugs , 2012, Nature Reviews Drug Discovery.

[31]  W. Nishio,et al.  Overexpression of Necl‐5 correlates with unfavorable prognosis in patients with lung adenocarcinoma , 2010, Cancer science.

[32]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[33]  M. Ziepert,et al.  Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Dimatteo,et al.  Physician Communication and Patient Adherence to Treatment: A Meta-Analysis , 2009, Medical care.

[35]  R. Gray,et al.  Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. , 2009, Cancer research.

[36]  R. A. Bailey,et al.  Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes , 2007, Nature Genetics.

[37]  L. Moretta,et al.  Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. , 2006, Blood.

[38]  T. Blankenstein.  The role of tumor stroma in the interaction between tumor and immune system. , 2005, Current opinion in immunology.

[39]  H. Nakauchi,et al.  CD226 (DNAM-1) Is Involved in Lymphocyte Function–associated Antigen 1 Costimulatory Signal for Naive T Cell Differentiation and Proliferation , 2003, The Journal of experimental medicine.

[40]  L. Moretta,et al.  Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.

[41]  K. Irie,et al.  Nectins and nectin‐like molecules: Roles in cell adhesion, migration, and polarization , 2003, Cancer science.

[42]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[43]  C. Drake,et al.  Molecular Pathways Molecular Pathways : Coexpression of Immune Checkpoint Molecules : Signaling Pathways and Implications for Cancer Immunotherapy , 2013 .

[44]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[45]  J. Todd,et al.  CD226 Gly307Ser association with multiple autoimmune diseases , 2009, Genes and Immunity.

[46]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.

[47]  Lewis L Lanier,et al.  NK cell recognition. , 2005, Annual review of immunology.

[48]  K. Calman,et al.  Immunological Aspects of Cancer Chemotherapy , 1980 .